NCT01774851View on ClinicalTrials.gov

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

PHASE2TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

December 31, 2015

Conditions
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction CancerStomach Cancer
Interventions
DRUG

MM-111

MM-111 (IV)

DRUG

Paclitaxel

Paclitaxel (IV)

DRUG

Trastuzumab

Trastuzumab (IV)

Trial Locations (21)

14263

Buffalo

15232

Pittsburgh

19111

Philadelphia

27710

Durham

33705

St. Petersburg

34471

Ocala

35294

Birmingham

37203

Nashville

43210

Columbus

44106

Cleveland

55905

Rochester

61801

Urbana

63110

St Louis

80218

Denver

89135

Las Vegas

90089

Los Angeles

90095

Los Angeles

94305

Stanford

98801

Wenatchee

02111

Boston

02114

Boston

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT01774851 - A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Biotech Hunter | Biotech Hunter